Evaluation Of Serum Matrix Metalloproteinase 2-7-9, Tissue Matrix Metalloproteinase ınhibitor 1, Vascular Endothelial Growth Factor, Interleukin 6 And Interleukin 8 Levels In Breast Cancinoma

Abstract

Purpose: The increased incidence of breast cancer and development of new treatment modalities improved significant survival so new markers are needed for better assesment and follow up. Serum matrix metalloproteinase 2, 7, 9 (MMP2, MMP7, MMP9), tissue matrix metalloproteinase inhibitor 1 (TIMP1), interleukin 6, interleukin 8 and vascular endothelial growth factor (VEGF) take different parts in carcinogenesis. The aim of this study was to evaluate the relationship between these markers and clinical stage, histopathologic features and laboratuary parameters. Materials and Methods: Seventy-eight pathologically proven, chemotherapy naive breast cancer patients were enrolled. The analyses were carried out using SPSS v15 and p<0.05 was accepted as significant. Descriptive studies were analyzed using chi-square test and Mann-Whitney U-test depending on group numbers. Results: The median age of patients were 52±11.6 years. Patients were divided into non-metastatic and metastatic groups. VEGF values were 3.4 fold higher in metastatic group. Higher CA15-3 levels were statistically correlated with MMP9 and IL6. The elevation of serum LDH were associated with elevated VEGF and TIMP1. CRP elevation was correlated with increased IL8, IL6 and MMP9. High levels of VEGF was associated with progression. VEGF levels of dead patients were higher although the difference was not significant. MMP7 levels were lower in hormon positive group while the MMP2 levels were higher in HER2 (3+) group. TIMP1 levels were lower in patients with a ki 67 ratio above 40%. Conclusion: This is the first study showing the correlation between serum MMP2 levels and HER2 positivity, and also the negative correlation between ki67 and serum TIMP1 levels. This preliminary study was performed with limited number of patients although shown the potential effect of new biomarkers in clinical prognosis of breast carcinoma. © 2019, Pamukkale University. All rights reserved.